Article Data

  • Views 2036
  • Dowloads 149

Original Research

Open Access

Targeting out-of-hospital cardiac arrest: the effect of heparin administered during cardiopulmonary resuscitation (T-ARREST)

  • JIØÍ KNOR1
  • MILANA POKORNÁ2
  • ROMAN ŠKULEC2
  • JIØÍ MÁLEK3
  • PETR WALDAUF3
  • ROMAN SKØIPSKÝ2
  • VLADIMÍR ÈERNÝ4

1,The Regional Centre of the Emergency Medical Service of the Central Bohemian Region Emergency Medical Service of the Capital City of Prague Department of Anaesthesiology

2,Emergency Medical Service of the Capital

3,Department of Anaesthesiology and Resuscitation of the 3rd Medical Faculty

4Department of Anesthesiology and Intensive Care, Charles University in Prague, Faculty of Medicine in Hradec Kralove, University Hospital Hradec Kralove

DOI: 10.22514/SV62.102011.3 Vol.6,Issue 2,October 2011 pp.24-30

Published: 31 October 2011

*Corresponding Author(s): JIØÍ KNOR E-mail: jiri.knor@centrum.cz

Abstract

Introduction. Heparin administration during cardiopulmonary resuscitation (CPR) may prevent activation of coagulation after successful resuscitation for out-of-hospital cardiac arrest (OHCA). We hypothesize that such an approach is not associated with an increased rate of bleeding, but it has not been evaluated. We performed a pilot randomized clinical study assessing the safety of intra-arrest heparin administration in OHCA patients with suspected acute myocardial infarction (AMI) and its impact on their prognosis. 

Materials and Methods. OHCA patients were randomized during CPR to 10 000 units of intra-arrest intravenous heparin (Group H) or to treatment without heparin (Group C). The occurrence of major bleeding and the presence of a favourable neurological result 3 months after OHCA, were analyzed.

Results. Out of 88 randomized patients, AMI was subsequently confirmed in 63 of them (71.6 %). There were 30 patients in group H and 33 in group C. No major bleeding event was observed in either group. Return of spontaneous circulation (ROSC, Group H: 40.0%, Group C: 45.4%, p=0.662) and a good neurological result 3 months after OHCA (Group H: 6.7 %, Group C: 9.1 %, p=0.921) did not differ between groups.

Conclusions. Intravenous administration of 10 000 units of heparin during CPR for OHCA in patients with supposed AMI was safe. We did not find any improvement in prognosis for our sample of limited size. Though the procedure proved safe, we recommend postponing the administration of heparin until ROSC, assessment of clinical state and recording of a twelve-lead ECG.

Keywords

out-of-hospital cardiac arrest, heparin, major bleeding

Cite and Share

JIØÍ KNOR,MILANA POKORNÁ,ROMAN ŠKULEC,JIØÍ MÁLEK,PETR WALDAUF,ROMAN SKØIPSKÝ,VLADIMÍR ÈERNÝ. Targeting out-of-hospital cardiac arrest: the effect of heparin administered during cardiopulmonary resuscitation (T-ARREST). Signa Vitae. 2011. 6(2);24-30.

References

1. Nolan JP, Neumar RW, Adrie C, Aibiki M, Berg RA, Böttiger BW, et al. Post-cardiac arrest syndrome: epidemiology, pathophysiology, treatment, and prognostication. A Scientific Statement from the International Liaison Committee on Resuscitation; the American Heart Association Emergency Cardiovascular Care Committee; the Council on Cardiovascular Surgery and Anesthesia; the Council on Cardiopul-monary, Perioperative, and Critical Care; the Council on Clinical Cardiology; the Council on Stroke. Resuscitation 2008;79:350-79.

2. Binks A, Nolan JP. Post-cardiac arrest syndrome. Minerva Anestesiol 2010;76:362-8.

3. Böttiger BW, Martin E. Thrombolytic therapy during cardiopulmonary resuscitation and the role of coagulation activation after cardiac arrest. Curr Opin Crit Care 2001;7:176-83.

4. Adams JA. Targeting the Endothelium. Signa vitae 2010;5(Suppl 1):17-23.

5. Böttiger BW, Arntz HR, Chamberlain DA, Bluhmki E, Belmans A, Danays T, et al.; TROICA Trial Investigators; European Resuscitation Council Study Group. Thrombolysis during resuscitation for out-of-hospital cardiac arrest. N Engl J Med 2008;359:2651-62.

6. Nolan JP, Deakin CD, Soar J, Böttiger BW, Smith G; European Resuscitation Council. European Resuscitation Council guidelines for resuscitation 2005. Section 4. Adult advanced life support. Resuscitation 2005;67 Suppl 1:S39-86.

7. Deakin CD, Nolan JP, Soar J, Sunde K, Koster RW, Smith GB,et al. European Resuscitation Council Guidelines for Resuscitation 2010 Section 4. Adult advanced life support. Resuscitation 2010;81:1305-52.

8. Stein PD, Hull RD, Raskob G. Risks for major bleeding from thrombolytic therapy in patients with acute pulmonary embolism. Consideration of non-invasive management. Ann Intern Med 1994;121:313-7.

9. Nolan JP, Morley PT, Hoek TL, Hickey RW, Advancement Life support Task Force of the International Liaison committee on Resuscitation.Therapeutic hypothermia after cardiac arrest. An advisory statement by the Advancement Life support Task Force of the International Liaison committee on Resuscitation. Resuscitation 2003;57:231-5.

10. Holmberg M, Holmberg S, Herlitz J. The problem of out-of-hospital cardiac-arrest prevalence of sudden death in Europe today. Am J Cardiol 1999;83:88D-90D.

11. Atwood C, Eisenberg MS, Herlitz J, Rea TD. Incidence of EMS-treated out-of-hospital cardiac arrest in Europe. Resuscitation 2005;67:75-80.

12. Böttiger BW, Motsch J, Böhrer H, Böker T, Aulmann M, Nawroth PP, et al. Activation of blood coagulation after cardiac arrest is not bal-anced adequately by activation of endogenous fibrinolysis. Circulation 1995;92:2572–8.

13. Varriale P, Maldonado JM. Echocardiographic observations during in-hospital cardiopulmonary resuscitation. Crit Care Med 1997;25:1717-20.

14. Ruiz-Bailén M, Morante-Valle A, Castillo-Rivera A, Pintor-Mármol A, Ramos-Cuadra JA, Expósito-Ruiz M, et al. Echocardiographic observa-tions during in-hospital cardiopulmonary resuscitation. Resuscitation 2006;71:264-6.

15. Memtsoudis SG, Rosenberger P, Loffler M, Eltzschig HK, Mizuguchi A, Shernan

SK, et al. The usefulness of transesophageal echocardiography during intraoperative cardiac arrest in noncardiac surgery. Anesth Analg 2006;102:1653-7.

16. Schneider A, Böttiger BW, Popp E. Cerebral resuscitation after cardiocirculatory arrest. Anesth Analg 2009;108:971-9.

17. Böttiger BW, Böhrer H, Böker T, Motsch J, Aulmann M, Martin E. Platelet factor 4 release in patients undergoing cardiopulmonary resuscitation--can reperfusion be impaired by platelet activation? Acta Anaesthesiol Scand 1996;40:631-5.

18. Gando S, Nanzaki S, Morimoto Y, Kobayashi S, Kemmotsu O. Out-of-hospital cardiac arrest increases soluble vascular endothelial adhe-sion molecules and neutrophil elastase associated with endothelial injury. Intensive Care Med 2000;26:38-44.

19. Gando S, Kameue T, Nanzaki S, Igarashi M, Nakanishi Y. Platelet activation with massive formation of thromboxane A2 during and after cardiopulmonary resuscitation. Intensive Care Med 1997;23:71-6.

20. Moliterno DJ. Advances in antiplatelet therapy for ACS and PCI. J Interv Cardiol 2008;21(Suppl 1):S18-S24.

21. Malý M. Atherothrombosis: the antiaggregant treatment. Cor vasa 2009;51(Suppl 1):19-21.

22. Spiel AO, Frossard M, Mayr FB, Kliegel A, Janata A, Uray T, et al. Pronounced platelet hyperfunction in patients with cardiac arrest achiev-ing restoration of spontaneous circulation. Crit Care Med 2009;37:975-9.

23. Kern KB, Sasaoka T, Higashi H, Hilwig RW, Berg RA, Zuercher M. Post resuscitation myocardial microcirculatory dysfunction is ameliorated with platelet glycoprotein IIb/IIIa inhibition. Circulation 2007;116:II630 –II631.

24. Böttiger BW, Bode C, Kern S, Gries A, Gust R, Glätzer R, et al. Efficacy and safety of thrombolytic therapy after initially unsuccessful car-diopulmonary resuscitation: a prospective clinical trial. Lancet 2001;357:1583–5.

25. Fatovich DM, Dobb GJ, Clugston RA. A pilot randomised trial of thrombolysis in cardiac arrest (The TICA trial). Resuscitation 2004;61:309–13.

26. Bozeman WP, Kleiner DM, Ferguson KL. Empiric tenecteplase is associated with increased return of spontaneous circulation and short term survival in cardiac arrest patients unresponsive to standard interventions. Resuscitation 2006;69:399–406.

27. Li X, Fu QL, Jing XL, Li YJ, Zhan H, Ma ZF, et al. A meta-analysis of cardiopulmonary resuscitation with and without the administration of thrombolytic agents. Resuscitation 2006;70:31–6.

28. Snyder-Ramos SA, Motsch J, Martin E, Böttiger BW. Thrombolytic therapy during cardiopulmonary resuscitation. Minerva Anestesiol 2002;68:186-91.

29. Spöhr F, Böttiger BW. Thrombolytic therapy during or after cardiopulmonary resuscitation. Efficacy and safety of a new therapeutic approach. Minerva Anestesiol 2003;69: 357-64.

30. Spöhr F, Böttiger BW. Thrombolytics in CPR. Current advantages in cardiopulmonary resuscitation. Minerva Anestesiol 2005;71:291-6.

31. Spöhr F, Böttiger BW. Safety of thrombolysis during cardiopulmonary resuscitation. Drug Saf 2003;26:367–79.

32. Crowell JW, Sharpe GP, Lambright RL, Read WL. The mechanism of death after resuscitation following acute circulatory failure. Surgery 1955;38:696-702.

33. Gaszyñski W. The use of protease inhibitor (trasylol) and heparin in cardiorespiratory resuscitation. I. Studies of the blood clotting system. Anaesth Resusc Intensive Ther 1975;3:125-34.

34. Matyal R, Grinberg AO, Panzica PJ, Darke M, Lerner AB, Fisher L, et al. Heparin administration during cardiopulmonary resuscitation. J Cardiothorac Vasc Anesth 2008;22:861-3.

35. Spaulding CM, Joly LM, Rosenberg A, Monchi M, Weber SN, Dhainaut JF, et al. Immediate coronary angiography in survivors of out-of-hospital cardiac arrest. N Engl J Med 1997;336:1629-33.

36. Kuisma M, Alaspää A. Out-of-hospital cardiac arrests of non-cardiac origin. Epidemiology and outcome. Eur Heart J 1997;18:1122-8.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Chemical Abstracts Service Source Index The CAS Source Index (CASSI) Search Tool is an online resource that can quickly identify or confirm journal titles and abbreviations for publications indexed by CAS since 1907, including serial and non-serial scientific and technical publications.

Index Copernicus The Index Copernicus International (ICI) Journals database’s is an international indexation database of scientific journals. It covered international scientific journals which divided into general information, contents of individual issues, detailed bibliography (references) sections for every publication, as well as full texts of publications in the form of attached files (optional). For now, there are more than 58,000 scientific journals registered at ICI.

Geneva Foundation for Medical Education and Research The Geneva Foundation for Medical Education and Research (GFMER) is a non-profit organization established in 2002 and it works in close collaboration with the World Health Organization (WHO). The overall objectives of the Foundation are to promote and develop health education and research programs.

Scopus: CiteScore 1.3 (2023) Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.

Embase Embase (often styled EMBASE for Excerpta Medica dataBASE), produced by Elsevier, is a biomedical and pharmacological database of published literature designed to support information managers and pharmacovigilance in complying with the regulatory requirements of a licensed drug.

Submission Turnaround Time

Conferences

Top